Extended-release naltrexone for alcohol and opioid dependence

A meta-analysis of healthcare utilization studies

Daniel M. Hartung, Dennis McCarty, Rongwei (Rochelle) Fu, Katharina Wiest, Mady Chalk, David R. Gastfriend

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Through improved adherence, once-monthly injectable extended-release naltrexone (XR-NTX) may provide an advantage over other oral agents approved for alcohol and opioid dependence treatment. The objective of this study was to evaluate cost and utilization outcomes between XR-NTX and other pharmacotherapies for treatment of alcohol and opioid dependence. Published studies were identified through comprehensive search of two electronic databases. Studies were included if they compared XR-NTX to other approved medicines and reported economic and healthcare utilization outcomes in patients with opioid or alcohol dependence. We identified five observational studies comparing 1,565 patients using XR-NTX to other therapies over 6. months. Alcohol dependent XR-NTX patients had longer medication refill persistence versus acamprosate and oral naltrexone. Healthcare utilization and costs was generally lower or as low for XR-NTX-treated patients relative to other alcohol dependence agents. Opioid dependent XR-NTX patients had lower inpatient substance abuse-related utilization versus other agents and $8170 lower total cost versus methadone.

Original languageEnglish (US)
Pages (from-to)113-121
Number of pages9
JournalJournal of Substance Abuse Treatment
Volume47
Issue number2
DOIs
StatePublished - 2014

Fingerprint

Naltrexone
Opioid Analgesics
Alcoholism
Meta-Analysis
Delivery of Health Care
Costs and Cost Analysis
Medication Adherence
Methadone
Health Care Costs
Substance-Related Disorders
Observational Studies
Inpatients
Therapeutics
Alcohols
Economics
Databases
Drug Therapy
Injections

Keywords

  • Alcohol dependence
  • Naltrexone
  • Opioid dependence

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology
  • Phychiatric Mental Health
  • Medicine (miscellaneous)
  • Medicine(all)

Cite this

Extended-release naltrexone for alcohol and opioid dependence : A meta-analysis of healthcare utilization studies. / Hartung, Daniel M.; McCarty, Dennis; Fu, Rongwei (Rochelle); Wiest, Katharina; Chalk, Mady; Gastfriend, David R.

In: Journal of Substance Abuse Treatment, Vol. 47, No. 2, 2014, p. 113-121.

Research output: Contribution to journalArticle

@article{3d794bf9cb614a5283964509ef1d890f,
title = "Extended-release naltrexone for alcohol and opioid dependence: A meta-analysis of healthcare utilization studies",
abstract = "Through improved adherence, once-monthly injectable extended-release naltrexone (XR-NTX) may provide an advantage over other oral agents approved for alcohol and opioid dependence treatment. The objective of this study was to evaluate cost and utilization outcomes between XR-NTX and other pharmacotherapies for treatment of alcohol and opioid dependence. Published studies were identified through comprehensive search of two electronic databases. Studies were included if they compared XR-NTX to other approved medicines and reported economic and healthcare utilization outcomes in patients with opioid or alcohol dependence. We identified five observational studies comparing 1,565 patients using XR-NTX to other therapies over 6. months. Alcohol dependent XR-NTX patients had longer medication refill persistence versus acamprosate and oral naltrexone. Healthcare utilization and costs was generally lower or as low for XR-NTX-treated patients relative to other alcohol dependence agents. Opioid dependent XR-NTX patients had lower inpatient substance abuse-related utilization versus other agents and $8170 lower total cost versus methadone.",
keywords = "Alcohol dependence, Naltrexone, Opioid dependence",
author = "Hartung, {Daniel M.} and Dennis McCarty and Fu, {Rongwei (Rochelle)} and Katharina Wiest and Mady Chalk and Gastfriend, {David R.}",
year = "2014",
doi = "10.1016/j.jsat.2014.03.007",
language = "English (US)",
volume = "47",
pages = "113--121",
journal = "Journal of Substance Abuse Treatment",
issn = "0740-5472",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Extended-release naltrexone for alcohol and opioid dependence

T2 - A meta-analysis of healthcare utilization studies

AU - Hartung, Daniel M.

AU - McCarty, Dennis

AU - Fu, Rongwei (Rochelle)

AU - Wiest, Katharina

AU - Chalk, Mady

AU - Gastfriend, David R.

PY - 2014

Y1 - 2014

N2 - Through improved adherence, once-monthly injectable extended-release naltrexone (XR-NTX) may provide an advantage over other oral agents approved for alcohol and opioid dependence treatment. The objective of this study was to evaluate cost and utilization outcomes between XR-NTX and other pharmacotherapies for treatment of alcohol and opioid dependence. Published studies were identified through comprehensive search of two electronic databases. Studies were included if they compared XR-NTX to other approved medicines and reported economic and healthcare utilization outcomes in patients with opioid or alcohol dependence. We identified five observational studies comparing 1,565 patients using XR-NTX to other therapies over 6. months. Alcohol dependent XR-NTX patients had longer medication refill persistence versus acamprosate and oral naltrexone. Healthcare utilization and costs was generally lower or as low for XR-NTX-treated patients relative to other alcohol dependence agents. Opioid dependent XR-NTX patients had lower inpatient substance abuse-related utilization versus other agents and $8170 lower total cost versus methadone.

AB - Through improved adherence, once-monthly injectable extended-release naltrexone (XR-NTX) may provide an advantage over other oral agents approved for alcohol and opioid dependence treatment. The objective of this study was to evaluate cost and utilization outcomes between XR-NTX and other pharmacotherapies for treatment of alcohol and opioid dependence. Published studies were identified through comprehensive search of two electronic databases. Studies were included if they compared XR-NTX to other approved medicines and reported economic and healthcare utilization outcomes in patients with opioid or alcohol dependence. We identified five observational studies comparing 1,565 patients using XR-NTX to other therapies over 6. months. Alcohol dependent XR-NTX patients had longer medication refill persistence versus acamprosate and oral naltrexone. Healthcare utilization and costs was generally lower or as low for XR-NTX-treated patients relative to other alcohol dependence agents. Opioid dependent XR-NTX patients had lower inpatient substance abuse-related utilization versus other agents and $8170 lower total cost versus methadone.

KW - Alcohol dependence

KW - Naltrexone

KW - Opioid dependence

UR - http://www.scopus.com/inward/record.url?scp=84903177521&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903177521&partnerID=8YFLogxK

U2 - 10.1016/j.jsat.2014.03.007

DO - 10.1016/j.jsat.2014.03.007

M3 - Article

VL - 47

SP - 113

EP - 121

JO - Journal of Substance Abuse Treatment

JF - Journal of Substance Abuse Treatment

SN - 0740-5472

IS - 2

ER -